References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPlatelet-rich plasma to treat patellar tendinopathies: a 1 year follow-up.
Kaux, Jean-François ULg; Croisier, Jean-Louis ULg; Bruyère, Olivier ULg et al

in Clinical Chemistry & Laboratory Medicine (2014, June), 52(Special Suppl), 1285

Background: Jumper’s knee is a frequent chronic overuse syndrome of the upper part of the patellar tendon. Platelets contain lots of growth factors which could enhance the healing process of tendons ... [more ▼]

Background: Jumper’s knee is a frequent chronic overuse syndrome of the upper part of the patellar tendon. Platelets contain lots of growth factors which could enhance the healing process of tendons. Infiltration of Platelet Rich Plasma (PRP) may be considered as a recent therapeutic option for chronic tendinopathies. The aim of the current study is to evaluate the clinical status and the return to sports activities in patients with chronic upper patellar tendinopathies up to 1 year after 1 infiltration of PRP. Methods: Twenty patients with chronic upper patellar tendinopathy were enrolled. Assessments were made before infiltration of PRP, and 6 weeks and 3 months and 1 year after the infiltration, using a 10-point Visual Analogic Scale and algofunctional scores (IKDC and VISA-P). Moreover, they had to answer an information questionnaire concerning their life and sports activities. The PRP was obtained with an apheresis system (COM.TEC, Fresenius). Six millilitres of PRP were injected without local anaesthetic. One week after infiltration, patients started a standardised sub-maximal eccentric reeducation. Results: Pain during daily activities significantly decreased with time. VAS has significantly dropped, IKDC and VISA-P significantly improved over the follow-up of 1 year. Seventy percents of patients reported a favourable evolution with decrease of pain, 15% did never report any improvement and 15% were treated surgically. Seventy percents returned to sports activities, 64,3% without any pain, and 50% of them recovered the same sport level. Younger patients seemed to be more susceptible to have an improvement of pain by the PRP infiltration. Conclusions: This study demonstrates that a local infiltration of PRP associated with a submaximal eccentric protocol can improve, at 1 year, symptoms of chronic jumper’s knee in patients non-responsive to classical conservative treatments. [less ▲]

Detailed reference viewed: 63 (3 ULg)
Full Text
See detailQuels types d'étude pour quels objectifs?
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Medi-Sphere (2014), 445

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailOne-year follow-up of platelet-rich plasma to treat chronic upper patellar tendinopathies
Kaux, Jean-François ULg; Croisier, Jean-Louis ULg; Bruyère, Olivier ULg et al

in European Journal of Physical and Rehabilitation Medicine (2014, May), 50(Suppl. 1 to No. 3), 227250-

Introduction: Infiltration of PRP may be used as a recent therapeutic option for chronic tendinopathies The aim of the current study is to evaluate the clinic and the return to sports activities in ... [more ▼]

Introduction: Infiltration of PRP may be used as a recent therapeutic option for chronic tendinopathies The aim of the current study is to evaluate the clinic and the return to sports activities in patients with chronic upper patellar tendinopathies 1 year after 1 infiltration of PRP. Material and methods: The follow-up of 20 subjects who beneficed from 1 infiltration of PRP was made before infiltration, after 3 months and 1 year after infiltration; it was made as follow: VAS, IKDC and VISA-P scores. Moreover, they had to answer an information questionnaire concerning their life and sports activities. Results: Seventy percents of patients reported a favourable evolution with decrease of pain, 10% did never report any improvement and 20% were treated surgically. Eighty-seven percents returned to sports activities without any pain, and 50% of them recovered the same sport level. VAS has significantly (p<0.0001) dropped, IKDC significantly improved (p=0.0007) and VISA-P also significantly increased (p=0.0087) over the follow-up of 1 year. Discussion: This study confirms that a local injection of PRP coupled with a program of eccentric rehabilitation through a chronic Jumper's knee, improves painful symptoms and the functionality of the subjects’ knee up to a follow-up of 1 year. [less ▲]

Detailed reference viewed: 71 (4 ULg)
Full Text
Peer Reviewed
See detailClinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg; Bellamy, Nicholas et al

in Rheumatology (2014), 53

Objectives. The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms in knee OA. Methods. Symptoms were assessed over 3 years in patients with primary knee OA receiving ... [more ▼]

Objectives. The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms in knee OA. Methods. Symptoms were assessed over 3 years in patients with primary knee OA receiving strontium ranelate 2 g/day (n = 454), 1 g/day (n = 445) or placebo (n = 472) in the Strontium Ranelate Efficacy in Knee Osteoarthritis Trial. Clinical response was evaluated using WOMAC subscores, minimal perceptible clinical improvement (MPCI), minimal clinically important improvement (MCII) and a modified OMERACT Osteoarthritis Research Society International (OARSI) responder definition. Patients who withdrew prematurely from the study were considered non-responders. Results. There was no significant effect on symptoms for strontium ranelate 1 g/day. At the dosage of 2 g/day, strontium ranelate was associated with greater response than placebo in terms of 520% improvement in WOMAC pain from baseline to the last visit (58% vs 47%, P = 0.002) and 550% improvement in WOMAC pain (42% vs 36%, P = 0.083). Significant differences were found in MPCI response for WOMAC pain (52% vs 40%, P<0.001), stiffness (47% vs 39%, P = 0.009) and physical function (46% vs 37%, P = 0.009) and in MCII response for WOMAC physical function (46% vs 37%, P = 0.013). There were also more OMERACT-OARSI-like responders with strontium ranelate (44% vs 35%, P = 0.004). The treatment placebo difference in MPCI response for WOMAC pain was significant after 6 months (P = 0.024), while that in MPCI and MCII response for WOMAC physical function reached significance after 12 months (P = 0.027 and P = 0.019, respectively). Conclusion. Treatment with strontium ranelate 2 g/day over 3 years is associated with a clinically meaningful improvement in pain from 6 months as well as physical function and stiffness as assessed by the number of responders above thresholds of clinical relevance. [less ▲]

Detailed reference viewed: 30 (14 ULg)
Full Text
See detailMais ce "p", que veut-il dire finalement ?
Bruyère, Olivier ULg; Dardenne, Nadia ULg

in Medi-Sphere (2014), 437

Detailed reference viewed: 30 (13 ULg)
Full Text
Peer Reviewed
See detailValidation des paramètres de marche par un système accélérométrique (Locométrix) à l’aide d’un système opto-électronique 3D (Coda Motion)
GILLAIN, Sophie ULg; Schwartz, C; Dramé, M et al

in Les Cahiers de l'Année Gérontologique (2014), 2(23), 724-73

Detailed reference viewed: 7 (3 ULg)
Full Text
Peer Reviewed
See detailPrévalence de la sarcopénie : impact de l'utilisation de différentes valeurs seuils de diagnostic
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Les Cahiers de l'Année Gérontologique (2014), 2(23), 513-75

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailAssociation entre la masse musculaire totale et la densité minérale osseuse de la hanche
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Les Cahiers de l'Année Gérontologique (2014), 2(23), 513-74

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailAssociation between lean mass and hip bone mineral density
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Arthritis and Rheumatism (2014), 66(11), 95

Detailed reference viewed: 6 (3 ULg)
Full Text
Peer Reviewed
See detailErratum to: Management of osteoporosis of the oldest old
Rizzoli, R; Branco, J; Brandi, ML et al

in Osteoporosis International (2014), 25

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailManagement of osteoporosis of the oldest old.
Rizzoli, R.; Branco, J.; Brandi, M.-L. et al

in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2014), 25

This consensus article reviews the diagnosis and treatment of osteoporosis in geriatric populations. Specifically, it reviews the risk assessment and intervention thresholds, the impact of nutritional ... [more ▼]

This consensus article reviews the diagnosis and treatment of osteoporosis in geriatric populations. Specifically, it reviews the risk assessment and intervention thresholds, the impact of nutritional deficiencies, fall prevention strategies, pharmacological treatments and their safety considerations, the risks of sub-optimal treatment adherence and strategies for its improvement. INTRODUCTION: This consensus article reviews the therapeutic strategies and management options for the treatment of osteoporosis of the oldest old. This vulnerable segment (persons over 80 years of age) stands to gain substantially from effective anti-osteoporosis treatment, but the under-prescription of these treatments is frequent. METHODS: This report is the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores some of the reasons for this and presents the arguments to counter these beliefs. The risk assessment of older individuals is briefly reviewed along with the differences between some intervention guidelines. The current evidence on the impact of nutritional deficiencies (i.e. calcium, protein and vitamin D) is presented, as are strategies to prevent falls. One possible reason for the under-prescription of pharmacological treatments for osteoporosis in the oldest old is the perception that anti-fracture efficacy requires long-term treatment. However, a review of the data shows convincing anti-fracture efficacy already by 12 months. RESULTS: The safety profiles of these pharmacological agents are generally satisfactory in this patient segment provided a few precautions are followed. CONCLUSION: These patients should be considered for particular consultation/follow-up procedures in the effort to convince on the benefits of treatment and to allay fears of adverse drug reactions, since poor adherence is a major problem for the success of a strategy for osteoporosis and limits cost-effectiveness. [less ▲]

Detailed reference viewed: 11 (4 ULg)
Full Text
Peer Reviewed
See detailOpportunity and challenges of eHealth and mHealth for patients and caregivers
Slomian, Justine ULg; Reginster, Jean-Yves ULg; Ethgen, Olivier ULg et al

in Austin Journal of Public Health and Epidemiology (2014), 1(2), 3-5

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailPrevalence of vitamin D inadequacy in European women aged over 80 years
Bruyère, Olivier ULg; Slomian, Justine ULg; Beaudart, Charlotte ULg et al

in Archives of Gerontology & Geriatrics (2014), 59

Inadequate vitamin D status is associated with secondary hyperparathyroidism and increased bone turnover and bone loss, which in turn increases fracture risk. The objective of this study is to assess the ... [more ▼]

Inadequate vitamin D status is associated with secondary hyperparathyroidism and increased bone turnover and bone loss, which in turn increases fracture risk. The objective of this study is to assess the prevalence of inadequate vitamin D status in European women aged over 80 years. Assessments of serum 25-hydroxyvitamin D levels (25(OH)D) were performed on 8532 European women with osteoporosis or osteopenia of which 1984 were aged over 80 years. European countries included in the study were: France, Belgium, Denmark, Italy, Poland, Hungary, United Kingdom, Spain and Germany. Two cut-offs of 25(OH)D inadequacy were fixed: <75 nmol/L (30 ng/ml) and <50 nmol/L (20 ng/ml). Mean (SD) age of the patients was 83.4 (2.9) years, body mass index was 25.0 (4.0) kg/m2 and level of 25(OH)D was 53.3 (26.7) nmol/L (21.4 [10.7] ng/ml). There was a highly significant difference of 25(OH)D level across European countries (p < 0.0001). In these women aged over 80 years, the prevalence of 25(OH)D inadequacy was 80.9% and 44.5% when considering cut-offs of 75 and 50 nmol/L, respectively. In the 397 (20.0%) patients taking supplemental vitamin D with or without supplemental calcium, the mean serum 25(OH)D level was significantly higher than in the other patients (65.2 (29.2) nmol/L vs. 50.3 (25.2) nmol/L; P < 0.001). This study indicates a high prevalence of vitamin D (25(OH)D) inadequacy in old European women. The prevalence could be even higher in some particular countries. [less ▲]

Detailed reference viewed: 28 (12 ULg)
Full Text
Peer Reviewed
See detailEffects of vitamin D in the elderly population : current status and perspectives
Bruyère, Olivier ULg; CAVALIER, Etienne ULg; Souberbielle, JC et al

in Archives of Public Health (2014), 72

Besides its well-known effect on bone metabolism, recent researches suggest that vitamin D may also play a role in the muscular, immune, endocrine, and central nervous systems. Double-blind RCTs support ... [more ▼]

Besides its well-known effect on bone metabolism, recent researches suggest that vitamin D may also play a role in the muscular, immune, endocrine, and central nervous systems. Double-blind RCTs support vitamin D supplementation at a dose of 800 IU per day for the prevention of falls and fractures in the senior population. Ecological, case–control and cohort studies have suggested that high vitamin D levels were associated with a reduced risk of autoimmune diseases, type 2 diabetes, cardio-vascular diseases and cancer but large clinical trials are lacking today to provide solid evidence of a vitamin D benefit beyond bone health. At last, the optimal dose, route of administration, dosing interval and duration of vitamin D supplementation at a specific target dose beyond the prevention of vitamin D deficiency need to be further investigated. [less ▲]

Detailed reference viewed: 21 (6 ULg)
Full Text
Peer Reviewed
See detailTraitement de l'osteoporose post-menopausique: quoi de neuf en 2014?
Reginster, Jean-Yves ULg; Neuprez, A.; Lecart, M. P. et al

in Revue medicale de Liege (2014), 69(7-8), 441-53

Management of osteoporosis involves both non pharmacological approaches, including changes in lifestyle and dietary habits combined, in patients at high risk of fracture or presenting with an established ... [more ▼]

Management of osteoporosis involves both non pharmacological approaches, including changes in lifestyle and dietary habits combined, in patients at high risk of fracture or presenting with an established osteoporosis, to the use of drugs. Besides supplementation in calcium and vitamin D (at daily doses of 1 gr and 800 IU) in patients whose dietary intakes do not cover the recommended daily allowances, medications to be used for the management of osteoporosis may include inhibitors of bone resorption (bisphosphonates, denosumab and selective estrogen receptor modulators), stimulators of bone formation (teriparatide) or chemical entities decreasing bone resorption and stimulating bone formation (strontium ranelate). The selection of a particular medication, for a single individual patient, will depend on the severity of the disease as well as on the patient's believes and expectations. Local, skeletal and systemic tolerance of the various drugs should also be taken into account. [less ▲]

Detailed reference viewed: 25 (6 ULg)
Full Text
Peer Reviewed
See detailValidation of an extended French version of ID MigraineTM as a migraine-screening tool
Streel, Sylvie ULg; Donneau, Anne-Françoise ULg; Dardenne, Nadia ULg et al

in Cephalalgia : An International Journal of Headache (2014)

Detailed reference viewed: 19 (11 ULg)